Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it has completed the assay design for the Company’s Point-of-Care (“POC”) solution for COVID-19 testing and is now generating
Headline results demonstrate VAL201 has potential to be a safe and well-tolerated drug
Genedrive® 96 SARS-CoV-2 Kit verified with Beckman Coulter Life Sciences RNA extraction chemistry
Deltex Medical has published its interim results to 30 June 2020.
Positive Coronavirus test results in shorter timescales
N4P has announced the appointment of Ardena Holding NV (‘Ardena’) as its contract development and manufacturing organisation (‘CDMO’) partner for the technology transfer and upscaling manufacture of Nuvec®, the Group’s unique silica nanoparticle
N4P has announced that Nuvec® loaded with coronavirus plasmid has successfully transfected Human Embryonic Kidney (“HEK”) cells in vitro and induced an expression of the spike protein in the cells.
The Coronavirus pandemic has had a massive impact on the UK economy. A contraction of more than 20 per cent in the three months to June, means that we are
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that Nuvec® loaded with Coronavirus plasmid
Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva
Beckman Coulter collaboration to automate high throughput SARS-CoV-2 PCR testing
